Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis

Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions

(2017) Kittika Yampayon et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy

(2016) Nagendra Chaudhary et al.   BMC Pediatrics

Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population

(2016) Wichittra Tassaneeyakul et al.   Pharmacogenetics and Genomics

Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population

(2016) C-C Chang et al.   PHARMACOGENOMICS JOURNAL

CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects

(2015) Valentina Franco et al.   Expert Opinion on Drug Metabolism & Toxicology

Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children

(2015) Supharat Suvichapanich et al.   JOURNAL OF HUMAN GENETICS

Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin

(2014) Wen-Hung Chung et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing

(2014) K E Caudle et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic Variants Associated With Phenytoin-Related Severe Cutaneous Adverse Reactions

(2014) Wen-Hung Chung et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01

(2014) J. Yun et al.   JOURNAL OF IMMUNOLOGY

Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response

(2013) J. Yun et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Relationship Between theHLA-B*1502Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

(2013) Wimonchat Tangamornsuksan et al.   JAMA Dermatology

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans

(2011) Hye-Ryun Kang et al.   Pharmacogenetics and Genomics

Pharmacokinetic and Pharmacodynamic Variation Associated with VKORC1 and CYP2C9 Polymorphisms in Thai Patients Taking Warfarin

(2010) Alisara Sangviroon et al.   Drug Metabolism and Pharmacokinetics

Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China

(2010) X.T. Wu et al.   EPILEPSY & BEHAVIOR

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population

(2008) Chaichon Locharernkul et al.   EPILEPSIA

Cross-sensitivity of skin rashes with antiepileptic drug use

(2008) L. J. Hirsch et al.   NEUROLOGY

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE